(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 4.99% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.
Gilead Sciences's revenue in 2026 is $29,087,000,000.On average, 30 Wall Street analysts forecast GILD's revenue for 2026 to be $38,209,210,349,531, with the lowest GILD revenue forecast at $35,307,260,711,334, and the highest GILD revenue forecast at $40,709,179,789,876. On average, 24 Wall Street analysts forecast GILD's revenue for 2027 to be $40,064,026,385,916, with the lowest GILD revenue forecast at $36,962,327,328,416, and the highest GILD revenue forecast at $43,655,793,894,501.
In 2028, GILD is forecast to generate $41,720,333,682,621 in revenue, with the lowest revenue forecast at $37,170,761,505,080 and the highest revenue forecast at $47,031,683,148,684.